Plazomicin (Zemdri)

[Plazomicin photo pending]

KEY POINTS

Plazomicin (Zemdri) is a “next generation” aminoglycoside antibiotic that has bactericidal concentration-dependent activity and works by inhibiting bacterial protein synthesis
Plazomicin is owned by Achaogen, Inc and was FDA-approved on June 26th of 2018 for complicated urinary tract infection in adults
- - The FDA did not approve it for the indication of bloodstream infection in adults
Plazomicin is active against some Gram negative bacteria (e.g., E. coli, K. pneumoniae, Enterobacter species) and some Gram positive bacteria (e.g., Staphylococcus aureus, including MRSA)
- Has reduced activity versus most Pseudomonas aeruginosa and Acinetobacter baumannii isolates
- Lacks activity against Enterococcus species, Streptococcus species, Stenotrophamonas maltophilia, and obligate anaerobes
- Plazomicin’s chemical structure allows it to remain active against some carbapenem-resistant organisms other aminoglycosides are inactive against
  - Plazomicin can resist certain aminoglycoside modifying enzymes
  - May not be effective for NDM-containing isolates, due to the frequent presence of aminoglycoside-resistance mechanisms
Primarily renal elimination and requires dose adjustment for renal dysfunction
Anticipated will be available IV only
Anticipated will be once-daily dosing
May require therapeutic drug monitoring
Carries boxed warnings for: nephrotoxicity, ototixicity, neuromuscular blockade, and fetal harm in pregnant mothers

RESOURCES